Evidence map›Paper›PMID 38914929›Full record

ArticleBMC neurology2024

A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy.

Sharon Wolters, Johannes A Carpay, Marja H Pronk, Karin W M Zuurbier, Maurice T Driessen, Leonidas Lyras, Maarten J Postma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sharon WoltersDepartment of Health Sciences, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen, 9713 GZ, The Netherlands. sharon@ascacademics.com.
Johannes A CarpayThe Migraine Clinic, Mariotteplein 60, Amsterdam, 1098 PA, The Netherlands.
Marja H PronkMH Pronk Health Care Consultancy Foundation, Leidsestraatweg, Woerden, 41D, 3443 BP, The Netherlands.
Karin W M ZuurbierTeva Netherlands B.V., Swensweg 5, Haarlem, 2031 GA, The Netherlands.
Maurice T DriessenTeva Pharmaceuticals, Piet Heinkade 107, Amsterdam, 1019 BR, The Netherlands.
Leonidas LyrasTeva Pharmaceuticals, Piet Heinkade 107, Amsterdam, 1019 BR, The Netherlands.
Maarten J PostmaDepartment of Health Sciences, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen, 9713 GZ, The Netherlands.

Funding

Teva Pharmaceuticals n/a
6 · The paper itself

Abstract

backgroundChronic migraine (CM) is the most severe and burdensome subtype of migraine. Fremanezumab is a monoclonal antibody that targets the calcitonin gene-related peptide pathway as a migraine preventive therapy. This study aimed to conduct a cost-effectiveness analysis of fremanezumab from a societal perspective in the Netherlands, using a Markov cohort simulation model.

methodsThe base-case cost-effectiveness analysis adhered to the Netherlands Authority guidelines. Fremanezumab was compared with best supportive care (BSC; acute migraine treatment only) in patients with CM and an inadequate response to topiramate or valproate and onabotulinumtoxinA (Dutch patient group [DPG]). A supportive analysis was conducted in the broader group of CM patients with prior inadequate response to 2-4 different classes of migraine preventive treatments. One-way sensitivity, probabilistic sensitivity, and scenario analyses were conducted.

resultsOver a lifetime horizon, fremanezumab is cost saving compared with BSC in the DPG (saving of €2514 per patient) and led to an increase of 1.45 quality-adjusted life-years (QALYs). In the broader supportive analysis, fremanezumab was cost effective compared with BSC, with an incremental cost-effectiveness ratio of €2547/QALY gained. Fremanezumab remained cost effective in all sensitivity and scenario analyses.

conclusionIn comparison to BSC, fremanezumab is cost saving in the DPG and cost effective in the broader population.

Indexed as

Antibodies, MonoclonalCost-Benefit AnalysisMigraine DisordersChronic DiseaseCost-Effectiveness AnalysisFemaleHumansMaleMarkov ChainsNetherlandsQuality-Adjusted Life YearsAntibodies, MonoclonalfremanezumabBurden of diseaseCalcitonin gene-related peptideChronic migraineCost effectivenessEconomic modelingFremanezumabHealth technology assessmentNetherlands

Identifiers

PMID38914929
PMCPMC11194870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.